The Latest Cardiac and Vascular News
SAN DIEGO, Jan. 07, 2019 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced the geographic expansion of its commercial operations in seven European countries with the addition of four new distribution partnerships. These partnerships will allow REVA to expand access to […]
SAN DIEGO, May 23, 2018 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, reported sustained safety and efficacy of the Fantom®bioresorbable scaffold (“BRS”) through two years based on data from the FANTOM II trial presented today at the EuroPCR conference in Paris, France. […]
SAN DIEGO, April 03, 2017 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce it has received CE Mark approval for its Fantom drug-eluting bioresorbable coronary scaffold, which offers multiple and substantial performance advantages over first-generation scaffolds on the market today. Fantom is REVA’s first commercial product. CE Marking […]
